Lilly acquisition of Dermira : US pharma giant Eli Lilly and Company (Lilly) has agreed to acquire California-based dermatology drug company Dermira for about $1.1 billion in an all-cash deal as per the latest pharma acquisition news. Dermira, which is being acquired for $18.75 per share, has been engaged in developing dermatology products for the […]
Eli Lilly and Company (Lilly) has initiated the phase 3 LIBRETTO-431 clinical trial to evaluate selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) in patients who are treatment-naïve. The US pharma company is aiming to enroll 400 patients in the late-stage clinical trial. The patients will be grouped randomly to be subjected to […]
Reyvow FDA approval : Eli Lilly and Company (Lilly) has bagged approval from the US Food and Drug Administration (FDA) for Reyvow (lasmiditan) for the acute treatment of migraine, irrespective of aura (a sensory phenomenon or visual disturbance), in adults. The oral treatment, which has been designed to bind to 5-HT1F receptors with high affinity, […]
Eli Lilly and Company has secured approval from the US Food and Drug Administration (FDA) for its migraine drug Emgality (galcanezumab-gnlm) as a preventative therapy for adults. The approval marks a significant milestone for Lilly, as Emgality becomes available as a once-monthly, self-administered, subcutaneous injection designed to help prevent migraines. Emgality, a calcitonin gene-related peptide […]
Strategic Expansion in Cancer Treatment: Eli Lilly and Company (Lilly), a leading US pharmaceutical firm, has finalized its acquisition of Armo BioSciences, a California-based immuno-oncology company, for $1.6 billion. This move is part of Lilly’s strategic initiative to enhance its immuno-oncology program, one of the most promising areas in cancer research today. Details of the […]
Lilly gastric cancer drug Cyramza (ramucirumab) did meet the primary endpoint of a phase 3 trial RAINFALL but could not improve overall survival of patients.
In a recent announcement, Eli Lilly and Company disclosed that its phase 3 RAINFALL trial of the drug Cyramza (ramucirumab) for the treatment of HER2-negative metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma achieved mixed results. While the trial met its primary endpoint of progression-free survival (PFS), it did not improve overall survival (OS), a key […]
Eli Lilly and Company (Lilly) has bagged the abemaciclib FDA approval to treat advanced breast cancer in patients whose breast cancer had progressed after taking therapy that changed their hormones (endocrine therapy).
Eli Lilly and Company (Lilly) has announced receiving U.S. Food and Drug Administration (FDA) approval for Verzenio (abemaciclib), to treat patients with metastatic breast cancer who have seen progression after previous treatment. This recent approval allows for the use of Verzenio in combination with fulvestrant in patients whose cancer has advanced on endocrine therapy. Detailed […]
Lilly’s breast cancer drug, abemaciclib given in combination with fulvestrant has met its primary endpoint of progression-free survival (PFS) in a phase 3 breast cancer trial.
Indianapolis-based pharmaceutical giant Lilly has announced positive outcomes from its phase 3 clinical trial, MONARCH 2, involving its innovative breast cancer treatment, abemaciclib, in combination with fulvestrant. This trial marks a significant advancement in the treatment of hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. Groundbreaking Results in Cancer Treatment The […]